Curriculum vitae
PERSONAL INFORMATION
Joao Freire
WORK EXPERIENCE
January 1993–December 1994
Medical doctor
Hospital de Pulido Valente, (Portugal)
Junior resident in training.
January 1995–February 2001
Medical doctor
Instituto Português de Oncologia, (Portugal)
Fellowship in Medical Oncology
2001–Present
Medical doctor
Instituto Português de Oncologia, (Portugal)
Assistant in Medical Oncology
November 2013–Present
Medical doctor
INFARMED - National Authority of Medicines and Health Products, I. P., (Portugal)
▪ Member of the drug evaluation committee
1997–Present
Clinical research
Instituto Português de Oncologia, (Portugal)
Paricipated as co-investigator, investigator and national coordinator in several clinical trials
EDUCATION AND TRAINING
October 1986–July 1992
Medical doctor
Faculdade de Ciências Médicas, Universidade Nova de Lisboa, (Portugal)
Medical school
2007–2008
Post-graduation in Palliative Care
Universidade Católica Portuguesa, (Portugal)
ADDITIONAL INFORMATION
Expertise
Medical Oncology
- anticancer drugs, support
Palliative care
Drug evaluation
Publications
Projects
Academic trials and publicly funded research:
- p53 Study ? First prospective Intergroup Translational Research Trial assessing the potential
predictive value of p53 using a
functional assay in yeast in patients with locally advanced/inflammatory or large operable breast
14/2/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 1 / 2
Curriculum vitae
Joao Freire
cancer prospectively randomised to
a taxane versus a non taxane regimen. (EORTC Breast Group Protocol n. 10994). Date of activation:
2001.
- "Ensaio de fase II de quimioradioterapia sequencial e concomitante no carcinoma espinocelular do
canal anal." (IPO-Lisbon). Date
of activation: 2002. Closed December 2006.
- Adjuvant Treatment of Fully Resected Stage III Colon Cancer with FOLFOX-4 versus FOLFOX-4
plus Cetuximab ? PETACC-8.
The EORTC "Gastrointestinal Tract Cancer Group". Date of activation: March 2007.
- "Estudo de adesão à terapêutica e efectividade de ECX (Epirubicina, Cisplatina e capecitabina ?
Xeloda®) no tratamento de
primeira linha de doentes com carcinoma gástrico metastático ou localmente avançado" (IPO ?
Lisbon)
- "Análise de minimização de custos de ECX em comparação com ECF no tratamento de primeira
linha de doentes com carcinoma
gástrico metastático ou localmente avançado" (IPO ? Lisbon)
- "Metástases hepáticas de carcinoma do cólon e recto ? Avaliação por RM da resposta à
quimioterapia neoadjuvante através da
quantificação dos valores do Apparent Diffusion Coeficient" (IPO ? Lisbon)
- Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma
of the stomach or the
esophagogastric junction, metastatic or not amenable to curative surgery according to HER2 and
EGFR status: a randomized phase
II trial. (EORTC Gastrointestinal Tract Cancer Group)
- Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal cancer "SPECTAColor"
(EORTC Gastrointestinal Tract
Cancer Group)
- INtegration of trastuzumab, with or without pertuzumab, iNto periOperatiVe chemotherApy of HER-2
posiTIVe stOmach caNcer:
The INNOVATION trial (EORTC Gastrointestinal Tract Cancer Group)
- Evaluation of diffusion weighted imaging -MRI in patients with resectable liver metastases from
colorectal cancer treated with
fluoropyrimidine-based chemotherapy as preoperative chemotherapy (EORTC Gastrointestinal Tract
Cancer Group; EORTC
Imaging Group)
- Low Rectal Cancer Study (MERCURY 2 Study Research Group)
- Homologous recombination deficiency as prognostic marker in metastatic gastric cancer. (Health
Cluster Portugal)
- InterAACT TRIAL (the International Rare Cancer Initiative (IRCI) group; EORTC Gastrointestinal
Tract Cancer Group)
Memberships
EORTC GastroIntestinal Tumors Study Group
Other Relevant Information
14/2/15
© European Union, 2002-2015 | http://europass.cedefop.europa.eu
Page 2 / 2